Tentarix Biotherapeutics, LP — Form D
Tentarix Biotherapeutics, LP of San Diego, CA, a company, filed a Form D exempt-offering notice with the SEC on 2023-09-07. The offering totals $35.0M, of which $35.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2023-09-07
- Form: D
- Accession: 0001822549-23-000002
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $35.0M
- Amount sold: $35.0M
- Investors: 5
- Date of first sale: 2023-08-28
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-491553
Issuer
- Name: Tentarix Biotherapeutics, LP
- CIK: 0001822549
- Entity type: Limited Partnership
- Jurisdiction: DELAWARE
- Incorporated: 2020
- Address: 10355 Science Center Drive, San Diego, CA, 92121
- Phone: 858-587-4815
Officers, directors & promoters (12)
| Name | Role | Location |
|---|
| Srinivas Akkaraju | Director | Palo Alto, CA |
| Thomas F Bumol | Director | San Diego, CA |
| Jerel Davis | Director | Alameda, CA |
| Paul Grayson | Director | San Diego, CA |
| Paul Kang | Director | San Diego, CA |
| Donald J Santel | Director | San Diego, CA |
| Allyson F Tighe | Director | San Diego, CA |
| Stephen F Demarest | Executive Officer | San Diego, CA |
| Paul Grayson | Executive Officer | San Diego, CA |
| Margaret F Karow | Executive Officer | San Diego, CA |
| Cory Freedland | Director | MENLO PARK, CA |
| Alyssa Lochbaum | Executive Officer | La Jolla, CA |
Other filings by this issuer (1)
More